Suzhou Ribo Life Science Co Ltd

Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertriglyceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercholesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases. Suzhou Ribo Life Science Co., Ltd. was incorporated in 2007 and is based in Kunshan, China.